Success Metrics

Clinical Success Rate
94.1%

Based on 16 completed trials

Completion Rate
94%(16/17)
Active Trials
2(10%)
Results Posted
19%(3 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_1
12
57%
Ph phase_2
8
38%
Ph not_applicable
1
5%

Phase Distribution

12

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
12(57.1%)
Phase 2Efficacy & side effects
8(38.1%)
N/ANon-phased studies
1(4.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

88.9%

16 of 18 finished

Non-Completion Rate

11.1%

2 ended early

Currently Active

2

trials recruiting

Total Trials

21

all time

Status Distribution
Active(3)
Completed(16)
Terminated(2)

Detailed Status

Completed16
Active, not recruiting2
Terminated1
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
2
Success Rate
94.1%
Most Advanced
Phase 2

Trials by Phase

Phase 112 (57.1%)
Phase 28 (38.1%)
N/A1 (4.8%)

Trials by Status

completed1676%
terminated15%
withdrawn15%
active_not_recruiting210%
not_yet_recruiting15%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT07421037Phase 1

Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older

Active Not Recruiting
NCT07421050Phase 1

Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older

Active Not Recruiting
NCT07126652Not Applicable

Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial

Not Yet Recruiting
NCT03014310Phase 1

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

Completed
NCT05664334Phase 1

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Completed
NCT00000779Phase 1

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

Completed
NCT00000832Phase 1

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

Completed
NCT00001042Phase 1

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

Completed
NCT00001046Phase 1

Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

Withdrawn
NCT00000868Phase 1

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

Completed
NCT03682120Phase 2

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Completed
NCT01097096Phase 2

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Completed
NCT02680002Phase 2

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

Completed
NCT03283319Phase 2

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

Completed
NCT00133497Phase 2

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

Completed
NCT01942265Phase 2

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Completed
NCT02213354Phase 2

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Completed
NCT01938742Phase 2

H7N9 Mix and Match With MF59 in Healthy Adults

Completed
NCT00280033Phase 1

H5 Adult - Chiron Study of Bird Flu Vaccine

Completed
NCT00912496Phase 1

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
21